Oncotelic to Present at the LD Micro Main Event XIX

Company Overview - Oncotelic Therapeutics, Inc. is a biopharmaceutical company focused on developing transformative medicines for cancer patients, utilizing its PDAOAI platform and expertise in nanomedicines and the tumor microenvironment [1][4] - The company has a special emphasis on rare pediatric cancers and holds rare pediatric designation for Diffuse Intrinsic Pontine Glioma (DIPG) through its joint venture [4] Recent Developments - Oncotelic will present at the 19th Annual Main Event on October 21, 2025, where CEO Vuong Trieu will discuss the company's progress and vision [1][3] - The lead program, Sapu, is a 45%-owned joint venture that is advancing in its nanomedicine platform, with key milestones in formulation optimization, regulatory engagement, and clinical trials [3] Event Details - The LD Micro Main Event XIX will take place from October 19 to 21, 2025, featuring around 120 companies presenting and engaging in one-on-one meetings with investors [3] - The event will include registration, keynote speakers, and company presentations over three days [3] Product Pipeline - Oncotelic has developed AL-101 for the intranasal delivery of apomorphine, targeting Parkinson's Disease, with over 60,000 new diagnoses annually in the U.S. and a projected increase to over 1.2 million patients by 2030 [5] - AL-101 is also being developed for Erectile Dysfunction (ED) and Female Sexual Dysfunction (FSD), addressing significant unmet medical needs in these areas [5][6]